GLIFAZ

Empagliflozin 5/10/20 mg tab

Indication

Indicated to treat type 2 diabetes.

Mode of Action

GLIFAZ is SGLT2 inhibitors. It block the SGLT2 at PCT and prevent the reabsorption of the glucose. This leads to the glycosuria reducing the blood glucose level.

Pharmacokinetics

Maximum concentration is achieve in 1.5 hours with bioavailability of 78%. Half-life is around 13 hours mainly excreted via urine.

Dosage and Recommendation

Recommended dose of empagliflozin is 10mg once daily, taken in the morning, with or without food. This may be increased upto 25mg once daily. Do not initiate empagliflozin if eGFR is below 45ml/min/1.73m2 and discontinue if eGFR fall below 45ml/min/1.73m2

Packing and Presentation

Each strip of GLIFAZ contains 10 tablets in a box of 10 x 3s Alu Alu packaging